Key Highlights0.34 is the consensus EPS estimate per the screener snapshot for Mitsubishi UFJ Financial Group, Inc. (NYSE:MUFG), against 0.4 for Sumitomo Mitsui and 0.17 for Mizuho, with all three call times listed as TNS and therefore unconfirmed.809.4 billion is the JPY first quarter …
Key HighlightsGevo (NASDAQ:GEVO) closed up 30.94% on November 11, 2026, after reporting record third quarter results on November 10.Revenue was about USD 83 million, nearly double a year earlier, andNet Incomeattributable to Gevo was about USD 22.7 million, or USD 0.09 per share.About USD …
Gross profit was USD 10.1 million, a 49% margin, compared with USD 10.8 million and 59% a year earlier. The CFO said revenue sharing with content partners, which can reach 50% or more of a given deal, and amortization of barter programming explain the …
Key Highlights2.71 billion is the USD snapshotMarket Valueof Cosan S.A. (NYSE:CSAN), the largest of five, ahead of USD 2.32 billion at Almonty, USD 1.82 billion at Twenty OneCapitaland USD 1 billion at Americas Gold.0.04 is the consensus EPS estimate per the screener snapshot for …
The company raised its full year outlook. It now expects 2026 net sales of USD 980 million to USD 990 million, compared with prior guidance that called for a decline of 3% to 5%, an adjustedOperating Marginof 5.5% to 6.5%, up from 4% to …
The company said it expects to finish its pre-feasibility study for the Richmond Hill project in the fourth quarter of 2026, with a feasibility study targeted for 2027. A metallurgical program reported on September 10 found that oxide lithologies other than transition material had …
Key Highlights0.04 is the consensus EPS estimate per the screener snapshot for Almonty, Americas Gold and Talon Metals, while Sigma Lithium stands at 0.08 and Anfield Energy at a loss estimate of 0.27.2.32 billion is Almonty's USDMarket Valueper the screener snapshot, ahead of USD …
On November 9, the company reported data from its HOPE-3 trial of 106 patients that met its primary upper limb endpoint at 12 months, and the shares rose 9.44%. Left ventricular ejection fraction favoured deramiocel by 1.8 points but missed statistical significance, with a …
Key HighlightsRevenue for the third quarter ended September 30, 2026 was a record USD 16.0 million, up 8.3% from USD 14.8 million, and management said growth would have been 9.7% excluding the spun-out Always Alpha.Net income was USD 0.23 million, or USD 0.02 per …
Key Highlights0.19 is the loss per share expected for Immix Biopharma, Eledon and Neumora per the screener snapshot, versus a loss of 0.95 at Immunic and 2.35 at Inhibrx, with only Neumora under USD 100 million in market value.232.1 million is Immix's USD cash …